Medicenna Therapeutics Announces Participation in Upcoming Conferences

TORONTO and HOUSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer as well as autoimmune and inflammatory diseases is pleased to announce its participation in several upcoming conferences. These events provide an opportunity for Medicenna to showcase its innovative therapies and engage with the industry and investment community.

Read more at globenewswire.com